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SummARy – The objective of this review was to analyze and compare the efficacy and safety of 
botulinum toxin for cosmetic oculofacial use, published in articles during the last two decades. Ar-
ticle searches for relevant data were conducted in 2009 for the last two decades. Controlled studies 
showed statistically significant improvement in glabellar, frontal, and lateral canthal wrinkles after 
botulinum toxin therapy. Standardized documentation using clinical examinations and grading by 
the patient and physician supports the efficacy of botulinum toxin in the treatment of dynamic wrin-
kles in the glabellar region, frontal region, and lateral canthal area. Complications and unwanted 
effects associated with the treatment were rare and temporary. Botulinum toxin is safe and efficacio-
us in the treatment of glabellar, frontal and lateral canthal wrinkles. Additional studies are required 
to assess the efficacy of botulinum toxin for other cosmetic indications. All available data suggest 
that the possible side effects are infrequent and completely resolved in short term after botulinum 
therapy. future research is needed to determine the ideal efficacious dose and concentration for each 
anatomic area. The use of botulinum toxin in conjunction with laser resurfacing treatment, facial 
surgical procedures, facial fillers, and other treatment modalities requires further study.
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Introduction
Botulinum toxin is one of the most potent toxins 
that blocks the release of acetylcholine at the neuro-
muscular junction. The use of botulinum toxin has 
spread through different subspecialties1-6 and is prob-
ably one of the most investigated usages wherever 
there is the need to block muscular activity.
Scott et al. first used botulinum toxin in 19737, and 
it was approved by the food and Drug Administra-
tion for use in the treatment of strabismus in 1979. 
it was used in the management of blepharospasm in 
1982. in 1989, the food and Drug Administration ap-
proved botulinum toxin for the treatment of hemifa-
cial spasm and blepharospasm. Demonstrated efficacy 
and safety of botulinum toxin for the treatment of 
blepharospasm, hemifacial spasm and strabismus, and 
the coincidental finding that facial wrinkles improved 
in the injected areas of patients treated for noncosmet-
ic indications, led to consideration of botulinum toxin 
for cosmetic indications. Cosmetic use of botulinum 
toxin was first reported in 19898, and Carruthers and 
Carruthers undertook systematic evaluation of botu-
linum toxin for cosmetic indications9-11.
The food and Drug Administration approved 
the use of botulinum toxin for glabellar wrinkles in 
2002. treatment of other areas like forehead, crow’s 
feet, nasal wrinkles, chin, and platysmal bands are 
off-label uses. Applications in the treatment of facial 
asymmetry involving the upper, middle and lower face 
and neck have been suggested8-11.
Botulinum toxin is used to treat conditions such 
as hyperhidrosis, tension headaches, migraine head-
aches, cervical dystonia, torticollis, adductor and 
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abductor laryngeal dystonia, lingual dystonia, limb 
dystonia, poststroke spasticity, back pain, and other 
conditions characterized by undesirable muscle con-
traction such as spastic conditions.
Botulinum toxin has been approved for blephar-
ospasm, axillary hyperhidrosis, strabismus, and cervi-
cal dystonia. The food and Drug Administration ap-
proved the cosmetic use of botulinum toxin type A for 
glabellar wrinkles in 200212.
table 1 summarizes the potential cosmetic uses of 
botulinum toxin that are suggested in current litera-
ture13.
with maximal frown. The incidence of complications 
was low, and the most common complication was 
mild ptosis (5.4%)14.
A placebo-controlled study in 273 patients as-
sessed efficacy for glabellar lines using a physician rat-
ing and found a statistically significant improvement 
in the botulinum toxin group versus placebo group 
(P<0.001), with a peak effect at 30 days. Side effects 
included headache in 11% of patients who received 
botulinum toxin and 20% of patients who received 
placebo, and blepharoptosis in 1% of patients who 
received botulinum toxin; 268 of 273 patients com-
pleted the study. follow-up in this study occurred at 
7, 30, 60, 90, and 120 days12. Both placebo-controlled 
studies found botulinum toxin to be safe and effica-
cious in reducing glabellar lines12,14.
A randomized study in 30 patients using 10 u of 
botulinum toxin injected in the glabellar area used a 
physician and a patient scale for outcome assessment. 
injections significantly reduced wrinkles in the botu-
linum toxin group at 2 and 12 weeks, with a duration 
of 17.8 weeks15.
A case series of 30 patients reports improvement in 
glabellar wrinkles with botulinum toxin injection. This 
study showed 62% elevation of the brow with 20 u of 
botulinum toxin. no adverse effects were reported16.
Glabellar and Forehead Wrinkles
two case series offered data on injection of the gla-
bellar area and forehead. Outcome of one study was 
assessed using digital overlay photography to stan-
dardize the patient position and lighting. The frontal 
area had more prolonged onset and duration of effect 
than the glabellar area. frontal muscle action was 35% 
at 2 weeks, and glabellar frowning was 7%. interbrow 
distance increased by 13% with the treatment17.
Another case series used botulinum toxin type A 
injections in 12 patients in 26 paired regions: 12 gla-
bellar, 10 orbicular, and 4 forehead. Patient estimate 
of efficacy was excellent in 3, very good in 4, good in 
2, and fair in 1, with 10 of 11 patients completing the 
survey. ecchymosis and brow ptosis were reported as 
adverse effects18.
Forehead Wrinkles
A dose-related response was noted in a random-
ized, double-masked, controlled trial showing greater 
upper face
 glabellar wrinkles
 upper nasalis wrinkles (bunny lines)
 lateral canthal wrinkles (crow’s feet)
 Horizontal forehead wrinkles
 Asymmetric brows
 Thyroid ophthalmopathy patients with pronounced  
  glabellar wrinkles
 lower eyelid wrinkles
midface
 lower nasalis wrinkles, nasal flare
 Short upper lip, gum show
 Perioral wrinkles (smokers’ lines)
 facial asymmetry
lower face
 mouth frown, melomental folds, drooping labial   
  commissure
 Peau d’orange chin
 mental crease
 lower facial asymmetry
neck
 Horizontal necklace lines
 Vertical platysmal folds
Glabellar Wrinkles
A multicenter double-blind study in 264 patients 
with moderate to severe glabellar wrinkles who re-
ceived injections of 20 u of botulinum toxin or pla-
cebo into 5 sites in the glabella showed a statistically 
significant reduction in the severity of wrinkles. The 
decrease in glabellar-line severity at rest persisted lon-
ger than the decrease in severity in the lines noted 
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efficacy and longer duration of effect in reducing hori-
zontal wrinkles with higher doses of botulinum toxin. 
The procerus and orbicular muscles were also included 
in the injection pattern. fifty-nine female patients 
were randomized to receive a total of 16, 32, or 48 u 
of botulinum toxin injected into 8 injection sites. The 
cosmetic benefits lasted longer than the direct action 
on contraction. Adverse reactions included headaches, 
local pain and swelling, and brow ptosis19.
Lateral Canthal and Lower Eyelid Wrinkles
A double-masked randomized study (n=60) com-
pared 6, 12, and 18 u of botulinum toxin in the orbic-
ular muscle of eye on one side and placebo on the other 
side. grading was documented at 4-week intervals for 
16 weeks. Results showed that botulinum toxin was 
efficacious in decreasing wrinkles (botulinum toxin 
vs. placebo, P≤0.045), with no dose-response relation-
ship20. no severe adverse reactions were noted. eleven 
percent to 25% in various treatment groups had mild 
bruising.
A randomized double-masked study in 10 women 
volunteers compared the use of botulinum types A 
and B for the treatment of lateral canthal wrinkles. All 
patients noted reduction of lateral canthal wrinkles. 
Botulinum type B produced slightly more discomfort 
on injection and more rapid onset but briefer duration 
of action. Return of wrinkles occurred in 60 days21.
Randomized subjects with moderate to severe 
crow’s feet at maximum smile (mild to severe at rest) 
received a single bilateral botulinum-A treatment (15, 
30, or 45 u) or placebo. Patient satisfaction was sig-
nificantly greater for all doses than for placebo for 16 
weeks (P<0.05 all). All doses were well tolerated22.
Conclusions
numerous studies support the short-term effi-
cacy and safety of botulinum toxin for several facial 
cosmetic indications. Patient satisfaction, physician 
evaluations, and photographic analysis in randomized 
double-masked controlled studies support the efficacy 
of botulinum toxin treatment of wrinkles in the gla-
bellar area, forehead and lateral canthus. more studies 
are required to assess the efficacy of botulinum toxin 
for other facial and neck cosmetic indications.
All available data suggest that short-term side 
effects are infrequent and completely resolved in no 
more than several months. The frequency of adverse 
periocular effects may be limited to some degree by 
certain precautions with dosage and injection tech-
nique. future research is needed to determine the 
ideal efficacious dose and concentration for each ana-
tomic area. The use of botulinum toxin in conjunction 
with laser resurfacing treatment, facial surgical pro-
cedures, facial fillers, and other treatment modalities 
requires further study.
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Sažetak
KOZmetSKA PRimJenA BOtulinum tOKSinA u PODRuČJu OČiJu i liCA
D. Šarić
Cilj ovoga prikaza je analiza i usporedba učinkovitosti i neškodljivosti upotrebe botulinum toksina za kozmetsku 
primjenu na licu objavljenih u literaturi tijekom posljednja dva desetljeća zaključno s 2009. godinom. Kontrolirane studije 
pokazale su statistički značajno poboljšanje bora na području čela, među obrvama te lateralnih kantalnih bora nakon tera-
pije botulinom toksinom. Standardizirana dokumentacija kliničkih pregleda kako ju ocjenjuju liječnici i klijenti govori u 
prilog djelotvornosti botulinum toksina u navedenim područjima lica. Komplikacije i neželjene pojave su rijetke i prolazne. 
terapija botulinum toksinom je sigurna i učinkovita u obradi bora glabelarne, frontalne i lateralne kantalne regije lica. 
Potrebne su dodatne studije za procjenu uspješnosti terapije botulinum toksinom za druge indikacije. Svi dostupni radovi 
govore u prilog činjenici da su moguće neželjene pojave nakon ove terapije rijetke i u potpunosti nestaju kroz kratko vri-
jeme od nastanka. Daljnja će istraživanja pokazati koje su doze i koncentracije botulinum toksina optimalne u pojedinoj 
anatomskoj regiji. upotreba botulinum toksina u kombinaciji s laserskom terapijom pojedinih regija lica, te kombinacije s 
ostalim tretmanima navedenih regija zahtijevaju daljnja istraživanja.
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